National Cancer Center Hospital East

This study tests whether a combination of targeted drugs (trastuzumab deruxtecan, capecitabine, and durvalumab) can shrink HER2-positive stomach or gastroesophageal junction cancer before surgery and prevent return after surgery. About 64 adults with untreated, advanced but not s…

This study tests whether combining two drugs, nivolumab and lenvatinib, can shrink tumors in people with anaplastic thyroid cancer that cannot be removed by surgery. About 51 adults with this rare and fast-growing cancer will receive the treatment. The main goals are to check saf…

This study tests a combination of three drugs (lenvatinib, pembrolizumab, and FLOT chemotherapy) given before and after surgery for stomach cancer. The goal is to see if this approach can shrink tumors significantly or make them disappear completely. The study involves 43 adults …